Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 243Stomach Neoplasms 23Breast Neoplasms, Male 16Neoplasm Metastasis 14Neoplasms 8Inflammatory Breast Neoplasms 8Esophageal Neoplasms 8Brain Neoplasms 8Colorectal Neoplasms 6Adenocarcinoma Of Esophagus 4Urologic Neoplasms 3Triple Negative Breast Neoplasms 3HER2-positive Breast Cancer 3Carcinoma, Non-Small-Cell Lung 3Carcinoma, Ductal, Breast 3Gallbladder Neoplasms 2Endometrial Neoplasms 2Cholangiocarcinoma 2Carcinoma, Lobular 2Carcinoma, Intraductal, Noninfiltrating 2Biliary Tract Neoplasms 2Adenocarcinoma 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Solid Cancers 1Rectal Neoplasms 1Prostatic Neoplasms 1Patient Preference 1Patient Compliance 1

Interventions

trastuzumab biosimilar HLX02 1Trastuzumab 1Taxes 1Radiotherapy 1Radiation 1Paclitaxel 1PF-05280014 1Ontruzant 1Ogivri 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Bladder Urothelial Carcinoma × Trastuzumab × Clear all
NCT00238420 2022-07-19

Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
70 enrolled 10 charts
Genitourinary

Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡